Genetic Technologies Limited (Nasdaq: GENE) to Ring The Nasdaq Stock Market Closing Bell

What: Genetic Technologies Limited (Nasdaq:GENE), a molecular diagnostics company specializing in women’s health, and provider of BREVAGenplus®, a first-in-class, clinically validated risk assessment test for sporadic breast cancer, will visit the Nasdaq MarketSite in Times Square.

In honor of the occasion, Eutillio Buccilli, Chief Executive Officer and Pippa Mann, race car driver in the Verizon IndyCar Series and BREVAGenplus spokesperson, will ring the Closing Bell. 

Where:Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast Studio

When:Friday, May 6, 2016 – 3:45 p.m. to 4:00 p.m. ET

Genetic Technologies Media Contact:Candice Knoll  Blueprint Life Science Group(415) 375 3340, Ext. [e-mail]  

Nasdaq MarketSite:Emily Pan(646) [e-mail]  

Feed Information:Fiber Line (Encompass Waterfront): 4463

Gal 3C/06C 95.05 degrees West 18 mhz Lower DL 3811 Vertical FEC 3/4 SR 13.235 DR 18.295411 MOD 4:2:0 DVBS QPSK

Social Media:For multimedia features such as exclusive content, photo postings, status updates and video of bell ceremonies, please visit our Facebook page:http://www.facebook.com/NASDAQ.

For photos from ceremonies and events, please visit our Instagram page:http://instagram.com/nasdaq

For livestream of ceremonies and events, please visit our YouTube page:http://www.youtube.com/nasdaq/live

For news tweets, please visit our Twitter page:http://twitter.com/nasdaq

For exciting viral content and ceremony photos, please visit our Tumblr page:http://nasdaq.tumblr.com/

Webcast: A live stream of the Nasdaq Closing Bell will be available at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx

Photos: To obtain a hi-resolution photograph of the Market Close, please go to http://business.nasdaq.com/discover/market-bell-ceremonies and click on the market close of your choice.

About Genetic Technologies LimitedGenetic Technologies is a molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women’s health. The Company’s lead product, BREVAGenplus®, is a clinically validated risk assessment test for non-hereditary breast cancer and is first in its class. BREVAGenplus improves upon the predictive power of the first generation BREVAGen test and is designed to facilitate better informed decisions about breast cancer screening and preventive treatment plans. BREVAGenplus expands the application of BREVAGen from Caucasian women to include African-Americans and Hispanics, and is directed towards women aged 35 years or above, who have not had breast cancer and have one or more risk factors for developing breast cancer. The Company has successfully launched the first generation BREVAGen test across the U.S. via its U.S. subsidiary Phenogen Sciences Inc. and the addition of BREVAGenplus, launched in October 2014, significantly expands the applicable market. The Company markets BREVAGenplus to healthcare professionals in comprehensive breast health care and imaging centres, as well as to obstetricians/gynaecologists (OBGYNs) and breast cancer risk assessment specialists (such as breast surgeons). For more information, please visit www.brevagenplus.com and www.phenogensciences.com.

About NasdaqNasdaq (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,700 listed companies with a market value of approximately $9.3 trillion and nearly 17,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.

-NDAQA-